IFRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
InflaRx N.V.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026
$1.45+0.13 (+9.85%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | Before market open | – | – | – |
Press releases
Announcements InflaRx filed with the SEC
FINANCIAL STATEMENTS – June 30, 2026
EX-99.1 to Form 6-K
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
InflaRx Reports Second Quarter 2026 Results and
EX-99.3 to Form 6-K
CORPORATE PRESENTATION AAV + RENAL STRATEGY May 2026
EX-99.2 to Form 6-K
FINANCIAL STATEMENTS – March 31, 2026
EX-99.1 to Form 6-K
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
EX-99.1 to Form 6-K
PRESS RELEASE, DATED APRIL 9, 2026
EX-99.1 to Form 6-K
The agenda for the AGM is as follows:
EX-99.1 to Form 6-K
acting on behalf of (only to be completed if relevant)
EX-99.2 to Form 6-K
PRESS RELEASE, DATED MARCH 19, 2026
EX-99.1 to Form 6-K
InflaRx Provides Update on Phase 3 Data Analyses
EX-99.1 to Form 6-K
InflaRx Reports Positive Phase 2a Data for INF904 in
EX-99.1 to Form 6-K
INF904 Topline Phase 2a Data Hidradenitis suppurativa (HS) & chronic
EX-99.2 to Form 6-K
FINANCIAL STATEMENTS – SEPTEMBER 30, 2025
EX-99.1 to Form 6-K
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
EX-99.1 to Form 6-K
INFLARX N.V. PRESS RELEASE DATED AUGUST 7, 2025
EX-99.3 to Form 6-K
FINANCIAL STATEMENTS – MARCH 31, 2025
EX-99.1 to Form 6-K
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
InflaRx Reports First Quarter 2025 Financial Results and
EX-99.3 to Form 6-K
acting on behalf of (only to be completed if relevant)
EX-99.2 to Form 6-K
InflaRx Reports Full Year 2024 Results and
EX-99.1 to Form 6-K
InflaRx Receives European Commission Approval for
EX-99.1 to Form 6-K
InflaRx Receives Positive CHMP Opinion for GOHIBIC®
EX-99.1 to Form 6-K
FINANCIAL STATEMENTS – SEPTEMBER 30, 2024
EX-99.1 to Form 6-K
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K